Literature DB >> 31187529

New drugs for new targets in lymphoma.

Anas Younes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31187529      PMCID： PMC6570411          DOI： 10.1002/hon.2592

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  19 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.

Authors:  Yan Li; Nilesh Chitnis; Hiroshi Nakagawa; Yoshiaki Kita; Shoji Natsugoe; Yi Yang; Zihai Li; Mariusz Wasik; Andres J P Klein-Szanto; Anil K Rustgi; J Alan Diehl
Journal:  Cancer Discov       Date:  2015-01-12       Impact factor: 39.397

3.  A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Authors:  Elayne Chan-Penebre; Kristy G Kuplast; Christina R Majer; P Ann Boriack-Sjodin; Tim J Wigle; L Danielle Johnston; Nathalie Rioux; Michael J Munchhof; Lei Jin; Suzanne L Jacques; Kip A West; Trupti Lingaraj; Kimberly Stickland; Scott A Ribich; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Roy M Pollock; Jesse J Smith; Olena Barbash; Melissa Pappalardi; Thau F Ho; Kelvin Nurse; Khyati P Oza; Kathleen T Gallagher; Ryan Kruger; Mikel P Moyer; Robert A Copeland; Richard Chesworth; Kenneth W Duncan
Journal:  Nat Chem Biol       Date:  2015-04-27       Impact factor: 15.040

4.  Inhibition of MALT1 protease activity is selectively toxic for activated B cell-like diffuse large B cell lymphoma cells.

Authors:  Uta Ferch; Bernhard Kloo; Andreas Gewies; Vera Pfänder; Michael Düwel; Christian Peschel; Daniel Krappmann; Jürgen Ruland
Journal:  J Exp Med       Date:  2009-10-19       Impact factor: 14.307

5.  Out of the jaws of death: PRMT5 steers p53.

Authors:  Shelley L Berger
Journal:  Nat Cell Biol       Date:  2008-12       Impact factor: 28.824

6.  EZH2: an epigenetic gatekeeper promoting lymphomagenesis.

Authors:  Holger Heyn; Manel Esteller
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

7.  Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

Authors:  Stephan Hailfinger; Georg Lenz; Vu Ngo; Anita Posvitz-Fejfar; Fabien Rebeaud; Montserrat Guzzardi; Eva-Maria Murga Penas; Judith Dierlamm; Wing C Chan; Louis M Staudt; Margot Thome
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

8.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Authors:  Csaba Bödör; Vera Grossmann; Nikolay Popov; Jessica Okosun; Ciarán O'Riain; King Tan; Jacek Marzec; Shamzah Araf; Jun Wang; Abigail M Lee; Andrew Clear; Silvia Montoto; Janet Matthews; Sameena Iqbal; Hajnalka Rajnai; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Erlend B Smeland; Wing C Chan; Rita M Braziel; Louis M Staudt; George Wright; T Andrew Lister; Olivier Elemento; Robert Hills; John G Gribben; Claude Chelala; András Matolcsy; Alexander Kohlmann; Torsten Haferlach; Randy D Gascoyne; Jude Fitzgibbon
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

9.  B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model.

Authors:  Almut Dufner; Wolfgang W Schamel
Journal:  Cell Commun Signal       Date:  2011-03-11       Impact factor: 5.712

10.  Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Authors:  Priscilla N Kelly; Donna L Romero; Yibin Yang; Arthur L Shaffer; Divya Chaudhary; Shaughnessy Robinson; Wenyan Miao; Lixin Rui; William F Westlin; Rosana Kapeller; Louis M Staudt
Journal:  J Exp Med       Date:  2015-11-30       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.